Discovery of a potent and selective aurora kinase inhibitor.
Oslob, J.D., Romanowski, M.J., Allen, D.A., Baskaran, S., Bui, M., Elling, R.A., Flanagan, W.M., Fung, A.D., Hanan, E.J., Harris, S., Heumann, S.A., Hoch, U., Jacobs, J.W., Lam, J., Lawrence, C.E., McDowell, R.S., Nannini, M.A., Shen, W., Silverman, J.A., Sopko, M.M., Tangonan, B.T., Teague, J., Yoburn, J.C., Yu, C.H., Zhong, M., Zimmerman, K.M., O'Brien, T., Lew, W.(2008) Bioorg Med Chem Lett 18: 4880-4884
- PubMed: 18678489 
- DOI: https://doi.org/10.1016/j.bmcl.2008.07.073
- Primary Citation of Related Structures:  
3D14, 3D15 - PubMed Abstract: 
This communication describes the discovery of a novel series of Aurora kinase inhibitors. Key SAR and critical binding elements are discussed. Some of the more advanced analogues potently inhibit cellular proliferation and induce phenotypes consistent with Aurora kinase inhibition. In particular, compound 21 (SNS-314) is a potent and selective Aurora kinase inhibitor that exhibits significant activity in pre-clinical in vivo tumor models.
Organizational Affiliation: 
Medicinal Chemistry, Sunesis Pharmaceuticals, 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA.